{
    "nct_id": "NCT04639219",
    "official_title": "A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology",
    "inclusion_criteria": "* Adults ≥18 years old. Other age restrictions may apply as per local regulations.\n* Unresectable and/or metastatic solid tumors with pre-specified HER2 mutations (S310F, S310Y, G660D, R678Q, D769Y, D769H, V777L, Y772_A775dup / A775_G776insYVMA, L755S, G778_P780dup / P780_Y781insGSP, T862A, and V842I locally determined by NGS or a validated nucleic acid-based methodology (eg, qPCR, digital PCR) on tumor tissue, who have progressed following prior treatment or who have no satisfactory alternative treatment options.\n* Prior HER2 targeted therapy is permitted.\n* All patients must provide an FFPE tumor sample for retrospective central HER2 testing.\n* LVEF ≥50%\n* ECOG 0-1\n* All patients have measurable target disease assessed by the Investigator based on RECIST v1.1\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 120 Years",
    "exclusion_criteria": "* HER2 overexpressing (IHC3+ or IHC2+/ISH+) breast, gastric or gastroesophageal junction adenocarcinoma.\n* HER2 mutant NSCLC.\n* Medical history of myocardial infarction within 6 months before randomization/enrolment, symptomatic CHF, unstable angina pectoris, clinically important cardiac arrhythmias, or a recent (< 6 months) cardiovascular event including stroke.\n* History of non-infectious pneumonitis/ILD, current ILD, or where suspected ILD cannot be ruled out by imaging at screening\n* Corrected QT interval by Fridericia's formula (QTcF) prolongation to > 470 msec (females) or > 450 msec (males) based on average of the screening triplicate 12-lead ECG.\n* Lung-specific intercurrent clinically significant severe illnesses.\n* History of active primary immunodeficiency, known HIV, active HBV or HCV infection\n* Uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals\n* Pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or Cell-free and Concentrated Ascites Reinfusion Therapy (CART).\n* Has spinal cord compression or clinically active central nervous system metastases.",
    "miscellaneous_criteria": ""
}